MILMED
FOR LIFE

# Milmed – A unique pharmabiotic product

We offer a unique pharmabiotic product that involves the production and examination of electromagnetic, millimeter wavelength-treated yeast cells.

## The probiotic product

Milmed is a patented method and a health-promoting agent based on 15 years of research into specially treated yeast cultures.

The current patented therapeutic areas, all with the same technology and product, include inflammatory conditions, allergies, and neurodegenerative disorders.

The company's product is now marketed as a food supplement, alnozine.com (with focus on allergies), but it is also on the journey of being registered as a medicinal product for the treatment of IBS.

## Highlights

- Three treatment areas protected worldwide in three patent families, of which two are granted and one is pending.
- Alnozine is marketed in Sweden since April 2023
- Production costs for the product are low which is indicated in the bulk procurement of 2 000 kg.
- The company is planning to initiate a Phase 1 clinical trial of the product, to generate supporting evidence in the treatment of IBS for classifying it as a medicinal product.
- The company have collaboration with Sapienza University, Orkla Group, CosmosID, Sandwalk BioVentures, Midas Pharma among others.

## Problem

- Irritable bowel syndrome (IBS) has been identified as one of the more highly prevalent and costly gastrointestinal disorders.
- The global prevalence of IBS is currently estimated at 15%, and IBS symptoms occur in about 10-20% of Westerners.
- Allergies pose a major global health issue. The incidence of allergies and other hypersensitivities has tripled in recent decades.
- Allergic rhinitis affects 10-30% of all adults and 40% of children. AR can cause sleeping problems including microarousals, leading to daytime fatigue and somnolence, and decreased cognitive functioning.
- Most companies work with bacterial strains which are less effective in the management of hard-to-treat therapeutic areas.

## Solution

- The company utilizes a patent-protected technology that allows for creation of treatment in several therapeutic areas.
- Milmed's technology initiates and stimulates rehabilitation processes in the human body by utilizing bioactive yeast cells with probiotic properties pre-treated with millimeter wavelengths.
- The product has demonstrated positive effects on inflammatory disorders in preclinical models.
- Treatment with the product has several therapeutic benefits, including enhancing general health condition and mood states, as well as having neuroprotective and neurorestorative properties.
- The non-toxicity of the product has been found repeatedly by in vitro studies, Sapienza University, in vivo studies (Uppsala) and through ingestion by over 500 individuals.

## In vitro studies 2023 at Sapienza University

mRNA expression of TGF- β (Anti-inflammatory cytokine)




mRNA expression of ARG-1 (M2 marker)




Human study 2022 (IBS/IBD)




Use of proceeds




## Achieved financing and R&D milestones

**€ 1.1M – Non-dilutive** | **€ 1.0M – Non-dilutive**

| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Research collaboration with Sapienza University, Rome. | Human preclinical studies initiated, allergies. | In vitro toxicity studies initiated, Sapienza. | Patent application for allergies filed. | Patent application for allergies granted. In vitro studies at Sapienza initiated, inflammatory diseases. | Human preclinical studies, IBS/IBD. Patent application for IBS/IBD filed. | PCT informs about granted patent application for IBS/IBD. In vivo, mechanism study. | Compile GRAS dossier and further studies of mechanism at CosmosID. Launching allergy product Alnozine in several EU markets. |

## Deal benchmarks

**US$ 1Billion**

Licensing agreement between Denali Therapeutics and Biogen in 2021. Parkinson´s disease in Phase 1b trial. + preclinical.

**US$ 300M**

Orkla Group acquired NutraQ (food supplement) in 2021.

## Future development milestones

**2023**

Launching Alnozine in US, Australia and three markets in Asia.
Toxicity study at RISE initiated.
Proposal for human depression study at Sapienza discussed.

**2024**

Phase I clinical trial.
Further studies on biomechanism.
Launching of Alnozine in additional markets.

**2025**

Phase II clinical trial.
Launching of Alnozine in additional markets.

**2026**

Data from Phase II clinical trial.
Launching of Alnozine in additional markets.

## Our team

The company has a highly experienced management and research team, currently comprised of CEO Thomas Lenz, Mr. Roger Karlsson (Financial Manager) and Tatiana Blomqvist (Production and Lab Manager). The research team is managed by professor Trevor Archer and professor Rita Businaro, Department of Medico-Surgical Sciences and Biotechnologies at Sapienza University in Rome. Dr. Luis Gosálbez is our specialty strategy and innovation expert focused on micro-biome technologies. The board contributes with important knowledge and experience from the Life Science field with Dr Anders Milton chairman, Anna Linton, boardmember and Sara Nikman, boardmember.




Read more about our team